S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
S&P 500   4,686.75
DOW   35,719.43
QQQ   397.83
NASDAQ:ACRS

Aclaris Therapeutics Stock Forecast, Price & News

$13.22
+0.58 (+4.59%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.56
$13.49
50-Day Range
$12.27
$18.49
52-Week Range
$3.47
$30.38
Volume
300,386 shs
Average Volume
1.20 million shs
Market Capitalization
$809.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.44
30 days | 90 days | 365 days | Advanced Chart
Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aclaris Therapeutics logo

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Headlines

Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Up 2.4%
November 30, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRS
Employees
59
Year Founded
N/A

Sales & Book Value

Annual Sales
$6.48 million
Book Value
$3.54 per share

Profitability

Net Income
$-51.01 million
Net Margins
-1,187.63%
Pretax Margin
-1,196.49%

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,206,000
Market Cap
$809.42 million
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/08/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

701st out of 1,394 stocks

Pharmaceutical Preparations Industry

333rd out of 673 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

Is Aclaris Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aclaris Therapeutics stock.
View analyst ratings for Aclaris Therapeutics
or view top-rated stocks.

How has Aclaris Therapeutics' stock price been impacted by COVID-19?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACRS shares have increased by 1,147.2% and is now trading at $13.22.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decline in short interest in the month of October. As of October 29th, there was short interest totaling 2,230,000 shares, a decline of 19.2% from the October 14th total of 2,760,000 shares. Based on an average trading volume of 422,400 shares, the days-to-cover ratio is currently 5.3 days. Approximately 4.9% of the shares of the stock are sold short.
View Aclaris Therapeutics' Short Interest
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Aclaris Therapeutics
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) released its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.07. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 54.41% and a negative net margin of 1,187.63%.
View Aclaris Therapeutics' earnings history
.

What price target have analysts set for ACRS?

4 Wall Street analysts have issued 12 month price objectives for Aclaris Therapeutics' stock. Their forecasts range from $26.00 to $49.00. On average, they expect Aclaris Therapeutics' stock price to reach $35.67 in the next twelve months. This suggests a possible upside of 169.8% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics CEO Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among Aclaris Therapeutics' employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (8.85%), Rock Springs Capital Management LP (6.21%), BlackRock Inc. (6.19%), Commodore Capital LP (3.58%), Renaissance Technologies LLC (3.30%) and BVF Inc. IL (2.24%). Company insiders that own Aclaris Therapeutics stock include David N Gordon, Frank Ruffo, Kamil Ali-Jackson and Neal Walker.
View institutional ownership trends for Aclaris Therapeutics
.

Which major investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Investments LP, Parkman Healthcare Partners LLC, Atom Investors LP, Assenagon Asset Management S.A., Point72 Asset Management L.P., Asymmetry Capital Management L.P., and Perceptive Advisors LLC. Company insiders that have sold Aclaris Therapeutics company stock in the last year include David N Gordon, Frank Ruffo, Kamil Ali-Jackson, and Neal Walker.
View insider buying and selling activity for Aclaris Therapeutics
or view top insider-selling stocks.

Which major investors are buying Aclaris Therapeutics stock?

ACRS stock was acquired by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Commodore Capital LP, Great Point Partners LLC, Invesco Ltd., BVF Inc. IL, Schonfeld Strategic Advisors LLC, and Jetstream Capital LLC.
View insider buying and selling activity for Aclaris Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $13.22.

How much money does Aclaris Therapeutics make?

Aclaris Therapeutics has a market capitalization of $809.42 million and generates $6.48 million in revenue each year. The biotechnology company earns $-51.01 million in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Aclaris Therapeutics have?

Aclaris Therapeutics employs 59 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

Where are Aclaris Therapeutics' headquarters?

Aclaris Therapeutics is headquartered at 640 LEE ROAD SUITE 200, WAYNE PA, 19087.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at (484) 324-7933, via email at [email protected], or via fax at 484-320-2344.


This page was last updated on 12/8/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.